

Vaccination Recommendations for Updated 2023-2024 mRNA COVID-19 Vaccines^{1,2}

Age	Dose/Vial Color	Not Previously Vaccinated	Previously Vaccinated
Pfizer/BioNTech Bivalent Vaccine (<i>Comirnaty</i>)			
6 months-4 years³	3 mcg/0.3 mL; yellow cap and label	3 doses: 1 st at week 0, 2 nd at week 3, and 3 rd ≥8 weeks after dose 2	1 previous Pfizer dose: 1 dose ≥3 weeks later and 1 dose ≥8 weeks after dose 2 2 previous Pfizer doses: 1 dose ≥8 weeks after last dose 3 previous Pfizer doses: 1 dose ≥2 months after last dose
5-11 years	10 mcg/0.3 mL; light blue cap and label	Single dose	1 dose ≥2 months after last dose of any mRNA COVID vaccine
≥12 years	30 mcg/0.3 mL; gray cap and label	Single dose	1 dose ≥2 months after last dose of any COVID vaccine
Moderna Bivalent Vaccine (<i>Spikevax</i>)			
6 months-4 years³	25 mcg/0.25 mL; dark blue cap/green label	2 doses 1 month apart	1 previous Moderna dose: 1 25-mcg dose ≥1 month after last vaccine ≥2 previous Moderna doses: 1 25-mcg dose ≥2 months after last vaccine
5-11 years	25 mcg/0.25 mL; dark blue cap/green label	Single dose	1 dose ≥2 months after last dose of any mRNA COVID vaccine
≥12 years	50 mcg/0.5 mL; blue cap and label	Single dose	1 dose ≥2 months after last dose of any COVID vaccine

1. The updated 2023-2024 formula vaccines include a monovalent component that corresponds to the Omicron variant XBB.1.5. Previous bivalent Moderna and Pfizer/BioNTech vaccines are no longer authorized for use in the US.
2. For immunocompetent persons. Persons with moderate or severe immunocompromise should receive a 3-dose initial series with at least one dose of the 2023-2024 COVID-19 vaccine and may receive 1 or more additional 2023-2024 COVID-19 vaccine doses based on the clinical judgement of a healthcare provider and personal preference and circumstances; additional doses should be given ≥2 months after the last 2023-2024 COVID-19 vaccine dose.
3. All doses should be homologous (i.e., from the same manufacturer).